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evaluation of the found publications demonstrated that the best reflection of the
conditions of routine practice (generalizability) in PRCTs can be obtained mostly
through the development of broader inclusion criteria, minimizing the exclusion
criteria or broadening the scope of patients evaluation. We found also suitable
tools, which can be used both during the design and evaluation of reliability of
PRCTs: PRECIS, PR-tool, Pragmascope tool or CONSORT. CONCLUSIONS: Properly
assessed PRCTs data in conjunction with information about the efficacy from RCTs
will serve as a whole to facilitate business decisions in medical practice, as well as
health organizations and rationalization of cost-reimbursement of used or new
medical technologies.
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HOW TO INCREASE PATIENT RETENTION RATE DURING THEIR PARTICIPATION
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OBJECTIVES: Collecting patient data in longitudinal studies is often a concern in
terms of data accuracy and patient follow-up. Physician assessment alone might be
not sufficient or feasible. Multiple strategies can maximize patient retention. The
methods to achieve these goals are intensive and made even more complex in
global studies where regulatory requirements vary across individual countries. The
objective of this research is to summarize the means used to improve patient
retention. METHODS: The selected methods for patient retention have been used
for three ongoing longitudinal safety registries requested by the European Medi-
cines Agency and/or the Food and Drug Administration RESULTS: Three studies
were conducted to assess safety follow-up over 20, 10 and 6 years, one of them was
Pediatric and all were evaluating drugs in Inflammatory Bowel Disease area. A total
of 8, 000 children and 13,250 adults have to be enrolled by Gastroenterologists in 27
countries. Maintaining long-term interest from investigators is essential. This is
aided by careful site selection and training and provision of targeted study mate-
rials like patient profiles and newsletters as we as fair compensation. To mitigate
patient attrition, these studies implemented direct-to-patient contact. This strat-
egy minimizes loss-to-follow-up and enables data collection directly from the pa-
tients, increasing data quality. Data can be supplemented through additional con-
tacts with relatives/legal guardians and/or other Health Care Providers. This
methodology needs to be detailed in the protocol and study material to provide, to
patients and the regulatory bodies, a clear overview of the procedures and respon-
sibilities in each country. CONCLUSIONS: A correlation between good comprehen-
sion of the stakes and study procedures by the sites and patient retention is com-
monly established. However, specific actions which target maintaining patient
interest and commitment is also important to successful retention. The means
must be adapted to the design and the patient population.
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METHODOLOGICAL CHALLENGES OF IQWIG’S EFFICIENCY FRONTIER CONCEPT
ELICITED BY MULTIPLE PATIENT-RELEVANT ENDPOINTS – WHY
PRIORITIZATION OF ENDPOINTS CANNOT BE AVOIDED
Neidhardt K, Wasmuth T
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OBJECTIVES: The Institute for Quality and Efficiency in Health Care (IQWiG) in
Germany evaluates benefits/harms and economic implications of medical inter-
ventions. For the purpose of cost-benefit analysis, IQWiG has developed the effi-
ciency frontier concept to determine the maximum reimbursable price for phar-
maceuticals. Within this concept benefits/harms are evaluated for each patient-
relevant endpoint. If a compound shows additional/less benefit or less/more harm
in several aspects of benefit, the creation of several efficiency frontiers would be
required. The objective of this contribution was to assess whether the existence of
multiple patient-relevant endpoints is a common feature within benefit assess-
ments according to article 35a Social Code Book V which would entail multiple
efficiency frontiers. METHODS: IQWiG’s homepage was browsed for completed
benefit assessments. Between January 2011 and May 2012, 21 benefit assessments
were published by IQWiG. All assessments were screened in detail for information
on patient-relevant endpoints and endpoint-specific benefit assessments.
RESULTS: In 11 dossier assessments, benefit was endpoint-specifically assessed,
whereas in 10 assessments, no endpoint-specific assessment was performed.
Within the 11 dossier assessments, 19 subpopulations with endpoint-specific as-
sessments were identified. For each subpopulation, between one and five end-
points were assessed by IQWiG. In total, 50 patient-relevant endpoints were de-
tected. On average 2.63 patient-relevant endpoints per subpopulation were
assessed. CONCLUSIONS: Since benefits/harms are evaluated for each patient-
relevant endpoint the existence of multiple patient-relevant endpoints constitute a
challenge for the compilation of the efficiency frontier and the subsequent deter-
mination of the maximum reimbursable price. Recommendations will likely be
imprecise due to endpoint-specific benefits/harms. Prioritizing and weighting ben-
efit and harm aspects can therefore not be avoided within IQWiG’s proposed effi-
ciency frontier concept if the decision maker requires precise recommendations
for the maximum reimbursable price. Thus, an aggregation of benefit and harm
parameters into one single efficiency frontier is needed.
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PLACEBO-CONTROLLED CLINICAL TRIALS: A DIFFICULT BALANCE
“JUSTIFICATION VERSUS FEASIBILITY” FOR ACADEMIC SPONSORS
Duracinsky M, Taron C, Matei M, Chassany O
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OBJECTIVES: In investigator-based clinical trials, the use of placebo is often justi-
fied as it increases the probability from the peers’ expertise of 1/ gaining a public
grant; 2/ publishing results in higher-rank journals. METHODS: Among the 139
randomized clinical trials (RCT) evaluating drugs and currently managed by the
Paris Hospitals, 68 are placebo-controlled. Aim is to analyze the hurdles in obtain-
ing the placebo and its justification. RESULTS:Half of the studies had difficulties in
obtaining the placebo. In rare cases, the study was unfeasible. When the placebo
concerns a new drug, the company may accept to provide the drug and its placebo,
at the eventual expense for the institutional sponsor to provide all the data without
any further compensation. It may be considered as a disguised industrial sponsor-
ship, the institutional sponsor while taking the responsibility of the study, being
relegated to a role of a CRO. Obtaining a placebo of an old drug is trickier since the
company may not sell anymore its product and generic companies are not able
and/or interested to manufacture the placebo. The request of a manufacturer can
be so expensive (up to 200.000€) that is exceeds by far the price of the verum, and of
the grant. The rationale for using a placebo as comparator is to ensure a double-
blind. However, when the drug administration is short (e.g. emergency setting), or
when the endpoint is “hard” (i.e. mortality, imaging, biology), it is unlikely that any
placebo effect from subjects and/or investigators may impact the endpoint assess-
ment. In such situations, the comparator may be “no treatment” with whenever
possible a blind assessment. CONCLUSIONS: Placebo-controlled RCT are challeng-
ing for institutional sponsors. Investigators and methodologists when writing a
protocol and peers’ expertise of a grant or a publication submission should con-
sider the necessity and the feasibility of placebo.
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SENSITIVITY ANALYSIS VERSUS UNCERTAINTY ANALYSIS IN HEALTH
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OBJECTIVE: To distinguish sensitivity analysis and uncertainty analysis, charac-
terize their differential roles in health economic decision making, and to provide
practical examples of their use and presentation in health economic analysis.
METHOD: The role of one-way sensitivity analysis is to quantify the impact of
varying a single parameter on the output of a model. However, this obscures an
important distinction between parameter uncertainty and variability. Sensitivity
analysis quantifies parameter variability in terms of the percentage change in a
model output for a given percentage change in a model input. Sensitivity is there-
fore an objective property of the model. Uncertainty analysis, on the other hand,
propagates a decision maker’s subjective parameter uncertainty through a model
to estimate the conditional uncertainty of the model output. Accordingly, the func-
tional role of sensitivity analysis is to help a decision maker to understand and
validate the internal model structure in order to gain trust in the model itself;
whereas the functional role of uncertainty analysis is to assess the potential impact
of a decision maker’s subjective parameter uncertainty on confidence in a partic-
ular model-based decision. These distinctive roles are both critical in health eco-
nomic analysis and decision making. We provide examples of sensitivity analysis
versus uncertainty analysis, show how to report the results of sensitivity and un-
certainty analyses, and discuss the implications of this distinction for conducting
one-way and probabilistic analyses. CONCLUSION: Confidence in model-based de-
cision making requires 1) confidence in the model itself, and 2) confidence in the
model output given one’s subjective parameter uncertainty. Sensitivity analysis
and uncertainty analysis, respectively, serve these differential roles.
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A NEW VALUE-BASED PRICING FRAMEWORK FOR THE OPTIMAL PRICING OF
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Three common methods of estimating optimal prices for pharmaceutical assets
are willingness-to-pay, health economic price appraisal, and reference price
benchmarking. PROBLEM: Each method has significant drawbacks. Willingness-to-
pay, assessed through primary research, can be limited by lack of knowledge of
product list prices and the disconnect between respondent answers and real-life
price acceptance. Health economic appraisals, utilizing cost-of-treatment models
to estimate the price at which new products are cost-effective, are subject to error,
interpretation, and are rarely accepted by stakeholders who drive price decisions.
Reference price benchmarking, using market analogues to gauge price points for
new products, does not take into account unique differences, perceived or real, of
assets. None of these methods are able to quantify market intangibles such as
unmet need and strength of competition. SOLUTION: To address these weak-
nesses, the authors have developed a mathematical framework using all three
pricing methodologies to triangulate on a price range. The Value-Based Pricing
Framework equation is a collection of activities that allows for the economic quan-
tification of an asset’s attributes, critical to determining an asset’s overall value-
based price. These activities include: 1) Willingness-to-pay Assessment: utilizes
qualitative and quantitative feedback from decision makers to understand price
expectations and thresholds vis-à-vis current competitors and comparators; 2)
Reference Price Benchmarking: Assesses pricing structure of comparators to pre-
dict performance; and 3) Health Economic Analysis: Estimates product pricing as a
function of health economic differentiation and determines cost-savings that can
be offset in price. CONCLUSION: Value-Based Pricing is a structured way of esti-
mating asset price based on its perceived value by various stakeholders. This flex-
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ible and adaptable framework can be applied to any therapeutic area and used to
evaluate any number of varying product profiles. It involves understanding how
stakeholders value asset attributes and how their willingness-to-pay helps quan-
tify each individual attributes’ contribution to a price.
PRM161
A PARADIGM SHIFT IN HEALTH ECONOMIC EVALUATIONS FOR DEVELOPING
COUNTRIES - OPTIMIZATION MODELLING FOR ASSESSING WHICH MIX OF
MALARIA PREVENTION STRATEGIES ACHIEVES A DEFINED PUBLIC HEALTH
TARGET AT THE LOWEST BUDGET
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Malaria remains one of the leading causes of ill health with the majority of cases
and deaths occurring in young children in Sub-Saharan Africa. Key interventions
currently recommended for preventing childhood malaria include Insecticide
Treated Nets, Indoor Residual Spraying, Intermittent Preventive Treatment in in-
fancy, and Seasonal Malaria Chemoprevention. One-to-one comparisons applied
in cost-effectiveness and budget impact analyses fail to examine the health and
economic impact of multiple interventions implemented simultaneously, and are
therefore unable to evaluate the optimal integration of available malaria preven-
tive interventions and partially efficacious vaccines currently in development.
Moreover, an incremental cost-effectiveness ratio with recommended willingness-
to-pay threshold provides limited guidance in developing countries. OBJECTIVE:
Defining an approach to identify the optimal sequence of introducing different
preventive interventions, achieving progressively increasing public health targets
for malaria control in children 5years old at the lowest budget. METHODS: Our
suggested optimization approach integrates two distinguished models to assess
combinations of interventions. A vector model simulates the impact of varying
coverages of vector control interventions on vector infectiousness capacity and
associated reduction in Entomological Inoculation Rate (EIR) for children. A human
host model applies this reduced EIR to simulate disease incidence at varying cov-
erages of interventions directly acting within humans. These connected models
provide all potential intervention combinations achieving a pre-defined public
health target (e.g. reducing childhood mortality with 50%). Considering malaria
policy evolutions at increasing public health targets, a lower bound is set on inter-
vention coverages at each optimization step. The remaining options are ranked
according to their budget impact considering cost of interventions and disease
management in a health system perspective. CONCLUSIONS: Using the optimiza-
tion process with progressively increasing public health targets provides an indi-
cation on the optimal sequence of introducing interventions at the lowest budget.
Therefore, this approach can support decision-making in prioritization of malaria
preventive interventions.
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APPROPRIATE COMPARATIVE TREATMENTS FOR EARLY BENEFIT ASSESSMENT
(EBA) IN GERMANY. COMPARING THE SUGGESTIONS BY THE JOINT FEDERAL
COMMITTEE (GBA) AND THE PHARMACEUTICAL COMPANIES
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OBJECTIVES: The selection of the appropriate comparator plays an important role
within the EBAs for innovative medicines in Germany. According to the law the
appropriate comparator typically has to be identified according to the standards of
evidence-based medicine. If there are several alternatives, the economics have to
be taken into consideration. Our aim was to explore differences in comparators as
suggested by the GBA and the pharmaceutical companies. METHODS: The review
includes EBAs that were started in 2011. The Joint Federal Committee’s (GBA) web-
page was used to obtain the respective company dossiers as well as the IQWiG
(Institute for Quality and Efficiency in Health Care) benefit assessments. The ap-
propriate comparators as stated by the companies and the GBA (according to the
IQWiG assessment) were extracted and compared. RESULTS: Twenty-four EBAs
were started in 2011. In 10 EBAs the pharmaceutical company applied the compar-
ator that was suggested by the GBA within the benefit dossier (Tafamidis Meglu-
min, Telaprevir, Abirateronacetat, Boceprevir, Ipilimumab, Fampridin, Belatacept,
Apixaban, Eribulin, Fingolimod), although in some of those cases data for the sug-
gested comparators e.g. for subgroups where not developed within the phase 3
clinical trials (Abirateronacetat, Fampridin, Fingolimod). In 9 EBAs no agree-
ment was reached (Linagliptin, Pirfenidon, Belimumab, Cannabis Sativa, Reti-
gabin, Aliskiren/Amlodipin, Collagenase, Cabazitaxel, Ticacrelor). For five drugs
no full dossier submissions and/or IQWiG assessments were conducted (Brom-
fenac, Dexmedetomidin, Pitavastatin, Regadenoson, Olmesartan/Amlodipin/
Hydrochlorthiazid). In seven EBAs GBA suggested ‘Best Supportive Care’ (BSC) as
appropriate comparator. In two cases optimized standard therapy was chosen
and in one EBA physiotherapy. CONCLUSIONS:Ongoing EBAs indicate a high level
of disagreement between comparators as suggested by GBA and respective com-
panies. Definition of BSC is different across various diseases and evidence levels for
BSC as appropriate comparator is scarce.
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ECONOMIC EVALUATIONS AND HEALTH TECHNOLOGY ASSESSMENTS IN THE
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OBJECTIVES: The expected value of perfect information (EVPI) assesses, at a given
willingness-to-pay threshold, the expected gain in net benefit from further re-
search to decrease uncertainty in a decision. If the EVPI exceeds the cost of obtain-
ing new information then further research is considered valuable. The parameters
for which further research is believed to be most valuable can be assessed by
calculating the expected value of perfect parameter information. The objective of
this analysis was to assess the use of EVPI in economic evaluations and health
technology assessment (HTA) from the perspective of the NHS in the UK.
METHODS: An unrestricted search was performed in MEDLINE for literature that
contained references to EVPI and cost-effectiveness analysis or HTA. The literature
obtained was assessed to establish the extent to which EVPI is used in economic
evaluation and HTA. Guidelines from the National Institute for Health and Clinical
Excellence (NICE) were also checked for references to EVPI. RESULTS:The literature
search indicated that out of 73,795 results for HTA or cost-effectiveness analysis,
only 70 (0.01%) of these also reported EVPI. There were 21 examples of calculating
the EVPI in an economic evaluation from a UK perspective; the earliest was pub-
lished in 2004. The NICE guide to the methods of technology appraisal (2008 update)
states that value-of-information methods can be used within a probabilistic sen-
sitivity analysis (PSA) to assess the contribution of uncertainty from each param-
eter to the overall decision uncertainty. However, the specification for manufac-
turer/sponsor submission of evidence does not explicitly request the EVPI to be
calculated as part of the PSA. CONCLUSION: The EVPI is a measure which can aid
decision makers by quantifying the value of further research in an area, but it is not
widely reported in published economic evaluations.
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ENSURING THE VALUE OF A MEDICAL DEVICE INNOVATION PRIOR TO MARKET
LAUNCH
Hidefjall P
KTH Royal School of Technology, Huddinge, Sweden
In order to ensure that new products entering health care markets are cost-effec-
tive over existing products Health Technology Assessment programs are imple-
mented in health care systems. Whereas HTA agencies can screen out underper-
forming products it is equally important that manufacturers implement
procedures to ensure that no underperforming products are developed and
brought to market in the first place. By analogy, there are standards that companies
need to comply with to ensure that their products are safe; similar standards or
methods to ensure that new products are cost-effective could be developed. Based
on 20 years experience of medical device innovation in industry, academia and
consulting a conceptual model to ensure cost-effective innovation is proposed. The
method divides the value assurance process into 3 Stages: concept generation,
concept validation and market entry strategy. During the concept generation phase
solutions to a critical problem with an unmet clinical need and a related disease
burden are generated and evaluated with the core group of clinicians and multiple
stakeholders according to costs, risks and benefits. The most promising concepts
are iteratively tested and validated according to freedom to operate, safety, effi-
cacy, ease-of-use, invasiveness, procedure success rate and head-to-head compar-
ative cost-effectiveness until a candidate product can be addressed to a target
patient group and practitioners at a profitable price. Finally, markets with the best
clinician community support, largest size, highest attainable prices and lowest
barriers to entry are addressed. This may sound as commonsense, but there are
some important evolutionary principles hidden: 1) downstream market selection
criteria are translated into early upstream tests; 2) multiple concepts are generated
to handle early uncertainty; and 3) iterative tests are performed until a satisfying
concept is selected. This model should ensure a product will pass HTA cost-effec-
tiveness evaluation if eventually exposed to it.
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VALIDATING HEALTH ECONOMIC MODELS: DEVELOPING A METHODOLOGICAL
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Models developed in Microsoft EXCEL of increasing complexity are being used as an
integral part of the submission process for new pharmaceutical products and for
technical assessments produced by national agencies. The credibility of the health
economic models utilised depends on their validity. Firstly, in terms of reflecting
the appropriate clinical process using the correct data and assumptions and sec-
ondly, in terms of ensuring a correct functioning of the model based on the rela-
tionships between variables and formulas embedded in the model. In this research,
the authors concentrate on the latter aspect of validating health economic models.
While recognising that models should be validated, there is a paucity of detailed
techniques available in the literature that show researchers and users of health
economic models how to validate them. Hence, we have attempted to develop a
methodological framework that may be helpful to both those reviewing complex
models and to model developers themselves who could incorporate validation
processes while they develop their own models. The authors have reviewed the
literature, looked at other disciplines (e.g. finance) where modelling plays a central
role, investigated different software options in addition to the inbuilt validation
tools in EXCEL. The evolving methodology has been applied to a number of existing
real-life models in order to develop a consistent approach. By applying the devel-
oped methodology, errors have been identified at the design/review stage in a
number of budget impact and cost-effectiveness models of varying degrees of com-
plexity. A consistent approach to validation is a useful tool to test the often highly
complex processes and relationships with thousands of formulas in health eco-
nomic models. It may also encourage modellers to take a more disciplined and
organised approach in the development process and give increased confidence to
end-users that the models they are using can be relied upon.
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